Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionAndrew H. Wei, Gail J. Roboz, Farhad Ravandi et al.|New England Journal of Medicine|2020Cited by 432
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First RemissionAndrew H. Wei, Gail J. Roboz, Hartmut Döhner et al.|Blood|2019Cited by 97
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J. Roboz, Hartmut Döhner, Farhad Ravandi et al.|Blood|2022Cited by 63